Physician profile
Ivan Ackerman
NPI 1609836089
$55,372.01
in general payments reported to CMS, 2019-2025
34 companies · $871 in 2025
The $871 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,078 · 2020: $13K · 2021: $15K · 2022: $11K · 2023: $10K · 2024: $1,338 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,704 · Food and Beverage: $2,812 · Education: $51.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,704.00 |
| Food and Beverage | $2,811.73 |
| Education | $51.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $24,979.80 | 2019-2025 | Trelegy Ellipta, Nucala |
| Mylan Specialty L.P. | $16,250.72 | 2019-2024 | Yupelri, Yupelri |
| Harmony Biosciences LLC | $7,390.58 | 2020-2025 | Wakix |
| Insmed, INC. | $2,640.90 | 2019-2025 | Arikayce |
| Astrazeneca Pharmaceuticals Lp | $1,007.35 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Jazz Pharmaceuticals INC. | $428.34 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.21 | 2019-2024 | Ofev, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $309.19 | 2022-2024 | Glassia |
| Regeneron Healthcare Solutions, INC. | $306.18 | 2019-2025 | Dupixent |
| Electromed, INC. | $262.72 | 2019-2024 | Smartvest |
| Inspire Medical Systems, INC. | $217.88 | 2023-2025 | Inspire |
| Mallinckrodt Hospital Products INC. | $170.40 | 2022-2025 | Acthar |
| Philips North America LLC | $149.04 | 2019-2020 | |
| Genzyme Corporation | $147.12 | 2019-2025 | |
| Amgen INC. | $112.45 | 2022-2025 | Tezspire |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $72.49 | 2023-2024 | Prolastin-C Liquid |
| Inogen, INC. | $49.35 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Sunovion Pharmaceuticals INC. | $48.85 | 2019 | |
| Verona Pharma, INC. | $45.59 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $41.57 | 2019-2023 | Opsumit, Uptravi |
| Baxter Healthcare | $38.62 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Pulmonx Corporation | $36.71 | 2022 | |
| Phadia US INC. | $35.70 | 2019-2023 | Immunocap |
| Janssen Pharmaceuticals, INC | $33.10 | 2019-2023 | Xarelto |
| United Therapeutics Corporation | $31.65 | 2023 | Tyvaso |
| E.R. Squibb & Sons, L.L.C. | $28.14 | 2019-2023 | |
| Axsome Therapeutics, INC. | $27.49 | 2023 | Sunosi |
| Vapotherm INC | $26.30 | 2022 | |
| Lilly USA, LLC | $25.36 | 2025 | Zepbound |
| Azurity Pharmaceuticals, INC. | $24.98 | 2025 | Alvesco |
| Pharming Healthcare, INC. | $24.17 | 2022 | |
| Viatris Specialty LLC | $20.32 | 2025 | Yupelri |
| Idorsia Pharmaceuticals US INC | $14.87 | 2023 | Quviviq |
| Circassia INC. | $14.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Ackerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.